Literature DB >> 24101298

Genetic shift of env V3 loop viral sequences in patients with HIV-associated neurocognitive disorder during antiretroviral therapy.

Christian Eggers1, Oliver Müller, Ingo Thordsen, Michael Schreiber, Axel Methner.   

Abstract

The development of human immunodeficiency virus type 1 (HIV)-associated neurocognitive disorder (HAND) involves the adaptation of viral sequences coding for the V3 loop of the env protein. The plasma and cerebrospinal fluid (CSF) may contain viral populations from various cellular sources and with differing pathogenicity. Combination antiretroviral therapy (cART) may alter the relative abundance of these viral populations, leading to a genetic shift. We characterized plasma and CNS viral populations prior to and during cART and relate the findings to viral elimination kinetics and the clinical phenotype. Longitudinal plasma and CSF samples of five chronically infected HIV patients, four of whom had HAND, and one seroconverter were analyzed for V3 sequences by RT-PCR and sequence analysis. In the chronically infected patients, pre-cART plasma and CSF viral sequences were different irrespective of viral elimination kinetics and clinical phenotype. cART induced replacement of plasma viral populations in all subjects. CSF viral populations underwent a clear genetic shift in some patients but remained stable in others. This was not dependent on the presence of HAND. The genetic shift of CSF V3 sequences was absent in the two subjects whose CSF viral load initially increased during cART. In one patient, pre- and post-treatment CSF sequences were closely related to the post-treatment plasma sequences, suggesting a common cellular source. We found heterogeneous patterns of genetic compartmentalization and genetic shift over time. Although these did not closely match viral elimination kinetics and clinical phenotype, the results imply different patterns of the dynamics and relative contribution of compartment-specific virus populations in chronic HIV infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24101298     DOI: 10.1007/s13365-013-0207-5

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  28 in total

Review 1.  Heterogeneity of HIV-1 and HIV-2.

Authors:  B T Korber; E E Allen; A D Farmer; G L Myers
Journal:  AIDS       Date:  1995       Impact factor: 4.177

2.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools.

Authors:  J D Thompson; T J Gibson; F Plewniak; F Jeanmougin; D G Higgins
Journal:  Nucleic Acids Res       Date:  1997-12-15       Impact factor: 16.971

3.  Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir.

Authors:  G Pialoux; S Fournier; A Moulignier; J D Poveda; F Clavel; B Dupont
Journal:  AIDS       Date:  1997-08       Impact factor: 4.177

4.  Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain.

Authors:  Y Liu; X P Tang; J C McArthur; J Scott; S Gartner
Journal:  J Neurovirol       Date:  2000-05       Impact factor: 2.643

5.  Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection.

Authors:  S Staprans; N Marlowe; D Glidden; T Novakovic-Agopian; R M Grant; M Heyes; F Aweeka; S Deeks; R W Price
Journal:  AIDS       Date:  1999-06-18       Impact factor: 4.177

6.  Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.

Authors:  M C Strain; S Letendre; S K Pillai; T Russell; C C Ignacio; H F Günthard; B Good; D M Smith; S M Wolinsky; M Furtado; J Marquie-Beck; J Durelle; I Grant; D D Richman; T Marcotte; J A McCutchan; R J Ellis; J K Wong
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

Review 7.  The neuropathogenesis of AIDS.

Authors:  Francisco González-Scarano; Julio Martín-García
Journal:  Nat Rev Immunol       Date:  2005-01       Impact factor: 53.106

8.  Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.

Authors:  Christian Eggers; Kurt Hertogs; Hans-Jörg Stürenburg; Jan van Lunzen; Hans-Jürgen Stellbrink
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

9.  HIV-1 V3 domain variation in brain and spleen of children with AIDS: tissue-specific evolution within host-determined quasispecies.

Authors:  L G Epstein; C Kuiken; B M Blumberg; S Hartman; L R Sharer; M Clement; J Goudsmit
Journal:  Virology       Date:  1991-02       Impact factor: 3.616

10.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01
View more
  4 in total

1.  Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.

Authors:  Michael J Peluso; Serena Spudich
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

Review 2.  [HIV 1-associated neurocognitive disorder: current epidemiology, pathogenesis, diagnosis and management].

Authors:  C Eggers
Journal:  Nervenarzt       Date:  2014-10       Impact factor: 1.214

Review 3.  Molecular Signatures of HIV-1 Envelope Associated with HIV-Associated Neurocognitive Disorders.

Authors:  Teresa H Evering
Journal:  Curr HIV/AIDS Rep       Date:  2018-02       Impact factor: 5.071

Review 4.  HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment.

Authors:  Christian Eggers; Gabriele Arendt; Katrin Hahn; Ingo W Husstedt; Matthias Maschke; Eva Neuen-Jacob; Mark Obermann; Thorsten Rosenkranz; Eva Schielke; Elmar Straube
Journal:  J Neurol       Date:  2017-05-31       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.